股票 
板块 
用户 
资讯 SHANDONG WEIFANG RAINBOW CHEMICAL CO., LTD The Third Quarter Financial Report of 2026
The Company and all members of the Board of Directors warrant that the information disclosed is true, accurate, and complete, without false records, misleading statements, or material omissions.
1. Consolidated Balance Sheet
Prepared by: Shandong Weifang Rainbow Chemical Co., Ltd
30 September, 2026
Unit: RMB
| Item | Closing balance | Opening balance |
| Current assets: | ||
| Monetary funds | 4,133,774,278.78 | 3,545,858,415.42 |
| Settlement provision | ||
| Lending to banks and other financial institutions | ||
| Financial assets held for trading | 9,788,545.20 | |
| Derivative financial assets | 4,993,868.53 | 4,263,716.98 |
| Notes receivable | 6,461,182.20 | 11,569,561.38 |
| Accounts receivable | 5,250,107,482.30 | 5,195,696,624.20 |
| Receivables financing | 2,453,804.14 | 477,415.21 |
| Pre-payments | 125,406,224.05 | 100,972,866.06 |
| Premium receivable | ||
| Re-insurance accounts receivable | ||
| Reserves for re-insurance contract receivable | ||
| Other receivables | 85,623,727.50 | 60,549,718.50 |
| Including: interest receivable | ||
| Dividends receivable | ||
| Financial assets purchased under resale agreement | ||
| Inventory | 3,536,801,638.57 | 2,653,810,498.34 |
| Including: Data resources | ||
| Contracted assets | ||
| Assets held for sale | 9,719,967.70 | 9,636,456.50 |
| Non-current assets that mature within one year | ||
| Other current assets | 502,737,448.91 | 358,606,869.13 |
| Total current assets | 13,667,868,167.88 | 11,941,442,141.72 |
| Non-current assets: | ||
| Disbursed loans and advances | ||
| Debt investments | ||
| Other debt investment | ||
| Long-term receivables | ||
| Long-term equity investment | 728,817.42 | 938,787.85 |
| Other equity instrument investment | ||
| Other non-current financial assets | ||
| Investment real estate | 6,496,786.09 | 7,263,907.46 |
| Fixed assets | 2,884,857,768.59 | 2,833,607,463.75 |
| Construction work in progress | 513,631,310.48 | 251,267,590.56 |
| Productive biological assets | ||
| Oil and gas assets | ||
| Assets with rights of use | 55,975,532.21 | 42,571,790.44 |
| Intangible assets | 350,034,804.45 | 346,009,832.70 |
| Including: Data resources | ||
| Development expenditure | 533,619,357.30 | 406,092,665.80 |
| Including: Data resources | ||
| Goodwill | 89,560,239.36 | 89,560,239.36 |
| Long-term deferred expenses | 20,272,134.40 | 26,098,818.90 |
| Deferred income tax assets | 428,310,275.07 | 403,051,310.07 |
| Other non-current assets | 55,139,031.26 | 63,663,107.82 |
| Total non-current assets | 4,938,626,056.63 | 4,470,125,514.71 |
| Total assets | 18,606,494,224.51 | 16,411,567,656.43 |
| Current liabilities: | ||
| Short-term loan | 2,652,542,925.97 | 1,704,533,162.11 |
| Borrowings from the central bank | ||
| Borrowing from banks and financial institutions | ||
| Financial liabilities held for trading | ||
| Derivative financial liabilities | 10,528,627.16 | 43,957,273.82 |
| Notes payable | 4,846,438,834.11 | 3,968,470,098.87 |
| Accounts payable | 1,683,867,984.09 | 1,377,868,841.20 |
| Advance receipts | ||
| Contract liability | 77,450,477.69 | 51,042,591.49 |
| Financial assets sold for repurchase | ||
| Deposits and interbank deposits received | ||
| Amount received from agency trading of securities | ||
| Amount received from agency underwriting of securities | ||
| Payroll payable | 325,538,057.20 | 316,866,749.65 |
| Taxes payable | 269,857,911.65 | 206,121,355.82 |
| Other payables | 70,860,216.79 | 82,123,529.85 |
| Including: Interests payable | ||
| Dividends payable | ||
| Charges and commissions payable | ||
| Re-insurance accounts payable | ||
| Liabilities held for sale | ||
| Non-current liabilities due within one year | 226,708,269.43 | 218,992,467.52 |
| Other current liabilities | 42,380,692.72 | 14,798,321.16 |
| Total current liabilities | 10,206,173,996.81 | 7,984,774,391.49 |
| Non-current liabilities: | ||
| Provision for insurance contracts | ||
| Long-term loan | 62,466,666.66 | 232,800,000.00 |
| Bonds payable | ||
| Including: Preferred shares | ||
| Perpetual bonds | ||
| Lease liability | 53,745,606.34 | 38,402,680.42 |
| Long-term payables | ||
| Long-term payroll payable | ||
| Accrued liabilities | 26,555,248.00 | 26,945,248.00 |
| Deferred income | 21,327,511.83 | 20,317,043.46 |
| Deferred income tax liabilities | 73,191,176.16 | 130,779,705.66 |
| Other non-current liabilities | ||
| Total non-current liabilities | 237,286,208.99 | 449,244,677.54 |
| Total liabilities | 10,443,460,205.80 | 8,434,019,069.03 |
| Owner's equity: | ||
| Share capital | 364,505,266.00 | 280,770,974.00 |
| Other equity instruments | ||
| Including: Preferred shares | ||
| Perpetual bonds | ||
| Capital reserve | 2,374,566,734.00 | 2,470,852,835.25 |
| Less: Treasury stock | 82,793,394.34 | 124,837,079.67 |
| Other comprehensive income | -83,660,568.38 | 27,594,464.95 |
| Special reserve | 32,368,895.29 | 40,641,595.53 |
| Surplus reserve | 179,435,014.25 | 158,674,657.07 |
| General risk reserve | ||
| Undistributed profit | 4,851,538,518.29 | 4,695,381,997.25 |
| Total owners' equity attributed to parent company | 7,635,960,465.11 | 7,549,079,444.38 |
| Minority shareholder's interest | 527,073,553.60 | 428,469,143.02 |
| Total owner's equity | 8,163,034,018.71 | 7,977,548,587.40 |
| Total liabilities and owners equity | 18,606,494,224.51 | 16,411,567,656.43 |
Legal Representative: Wicky Wang Chief Accountant in Charge: Xing Bingpeng Chief of Accounting Institution: Zhang Baolin
2. Consolidated income statement from the start of 2026 to the end of Q3 2026
Unit: RMB
| Item | Nine months ended September 30, 2026 | Nine months ended September 30, 2025 |
| I. Gross Operating Income | 11,510,518,545.73 | 10,911,452,781.83 |
| Including: Operating income | 11,510,518,545.73 | 10,911,452,781.83 |
| Interest income | ||
| Premium earned | ||
| Handling charges and commissions income | ||
| II. Total Operating Costs | 10,343,219,490.10 | 9,410,987,950.18 |
| Including: Costs of business | 8,730,029,798.31 | 8,501,898,847.49 |
| Interest expenses | ||
| Handling charges and commission expenses | ||
| Surrender value | ||
| Net payments for insurance claims | ||
| Net withdrawal of reserve for insurance responsibility contracts | ||
| Expenditures of policy dividend | ||
| Re-insurance expense | ||
| Taxes and surcharges | 48,014,603.71 | 49,558,778.47 |
| Sales expenses | 590,693,593.84 | 541,276,149.24 |
| Management expenses | 419,832,673.67 | 401,415,429.92 |
| R&D expenditures | 151,892,506.71 | 133,772,534.32 |
| Financial expenses | 402,756,313.86 | -216,933,789.26 |
| Including: Interest expenses | 56,170,672.20 | 75,022,595.81 |
| Interest income | 45,238,807.50 | 32,405,171.62 |
| Add: Other incomes | 4,912,278.27 | 4,654,362.94 |
| Income from investment ("-" for loss) | -82,419,145.45 | -16,249,258.28 |
| Including: Income from investment in associated enterprises and joint ventures | -209,970.43 | -225,713.45 |
| Income recognized at termination of financial assets measured at amortized cost | ||
| Foreign exchange gain ("-" for loss) | ||
| Net exposure hedging income ("-" for loss) | ||
| Income from changes in fair value ("-" for loss) | 34,033,509.75 | -128,100,023.82 |
| Credit impairment losses ("-" for loss) | -90,688,450.19 | -114,676,622.01 |
| Asset impairment losses ("-" for loss) | -10,028,264.20 | -2,428,761.50 |
| Gains from asset disposal ("-" for loss) | 539,272.77 | 165,266.75 |
| III. Operating Profit ("-" for loss) | 1,023,648,256.58 | 1,243,829,795.73 |
| Add: Non-operating income | 5,940,036.33 | 5,315,310.98 |
| Less: Non-operating expenses | 10,807,778.25 | 17,152,244.50 |
| IV. Total Profit Before Tax ("-" for total losses) | 1,018,780,514.66 | 1,231,992,862.21 |
| Less: Income tax expenses | 192,123,282.23 | 234,569,908.14 |
| V. Net Profit ("-" for net loss) | 826,657,232.43 | 997,422,954.07 |
| (I) Classification by business continuity | ||
| 1. Net profit from continuing operations ("-" for net loss) | 826,657,232.43 | 997,422,954.07 |
| 2. Net profit from discontinued operations ("-" for net loss) | ||
| (II) Classification by ownership | ||
| 1. Net profit attributable to shareholders of the parent company | 711,420,777.82 | 889,733,619.13 |
| 2. Profit and loss of minority shareholders | 115,236,454.61 | 107,689,334.94 |
| VI. Net Amount after Tax of Other Comprehensive Income | -111,255,033.33 | -57,800,314.71 |
| Net amount of other comprehensive income after tax attributed to the owners of parent company | -111,255,033.33 | -57,800,314.71 |
| (I) Other comprehensive income that cannot be reclassified into profit or loss | ||
| 1. Changes due to re-measurement on defined benefit plan | ||
| 2. Other comprehensive income that cannot be converted into profit and loss under the equity method | ||
| 3. Changes in fair value of other equity instrument investments | ||
| 4. Changes in the fair value of the credit risk of the enterprise | ||
| 5. Other | ||
| (ii) Other comprehensive income that will be reclassified into profit and loss | -111,255,033.33 | -57,800,314.71 |
| 1. Other comprehensive income that can be converted to profit or loss under the equity method | ||
| 2. Changes in fair value for other investment on bonds | ||
| 3. Amount of financial assets reclassified into other comprehensive income | ||
| 4. Provision for credit impairment of other creditor's rights investment | ||
| 5. Cash flow hedge reserve | ||
| 6. Difference of foreign currency financial statement translation | -111,255,033.33 | -57,800,314.71 |
| 7. Other | ||
| Net amount of other comprehensive income after tax attributed to minority shareholders | ||
| VII. Total Comprehensive Income | 715,402,199.10 | 939,622,639.36 |
| Total comprehensive income attributed to parent company owners | 600,165,744.49 | 831,933,304.42 |
| Total comprehensive income attributed to minority shareholders | 115,236,454.61 | 107,689,334.94 |
| VIII. Earnings per Share: | ||
| (i) Basic earnings per share | 1.96 | 2.46 |
| (ii) Diluted earnings per share | 1.96 | 2.45 |
Legal Representative: Wicky Wang Chief Accountant in Charge: Xing Bingpeng Chief of Accounting Institution: Zhang Baolin
3. Consolidated cash flow statement from the start of 2026 to the end of Q3 2026
Unit: RMB
| Item | Nine months ended September 30, 2026 | Nine months ended September 30, 2025 |
| I. Cash Flows Generated from Operating Activities: | ||
| Cash received from sales of goods and services | 11,522,832,099.95 | 10,927,180,152.79 |
| Net increase in deposit from customers and interbank | ||
| Net increase in borrowing from central bank | ||
| Net increase in borrowings from other financial institutions | ||
| Cash receipts from premiums under direct insurance contracts | ||
| Net cash receipts from re-insurance business | ||
| Net cash receipts from policyholders' deposits and investments | ||
| Cash receipts from interest, handling fees and commissions | ||
| Net increase in capital borrowed from banks and other financial institutions | ||
| Net increase in repurchase business capital | ||
| Net cash received from securities trading brokerage | ||
| Cash receipts from tax refunds | 734,305,981.10 | 682,472,830.95 |
| Cash received relating to other operating activities | 56,091,122.10 | 45,534,591.11 |
| Subtotal of cash inflow in business activities | 12,313,229,203.15 | 11,655,187,574.85 |
| Cash payments for goods acquired and services received | 9,564,071,085.27 | 8,193,069,943.45 |
| Net increase in customer loans and advances | ||
| Net increase in deposits in central bank and interbank | ||
| Cash payments for original insurance contract claims | ||
| Net increase in lending funds from banks and other financial institutions | ||
| Cash payments for interest, fee and commission | ||
| Cash payments for insurance policyholder dividends | ||
| Cash payments to employees and on behalf of employees | 906,626,081.56 | 749,380,596.43 |
| Cash payments for taxes | 309,438,433.57 | 234,736,883.10 |
| Other cash payments relating to operating activities | 763,277,417.84 | 737,685,814.09 |
| Subtotal of cash outflow in business activities | 11,543,413,018.24 | 9,914,873,237.07 |
| Net cash flow from operating activities | 769,816,184.91 | 1,740,314,337.78 |
| II. Cash Flows from Investing Activities: | ||
| Cash receipts from investment withdrawal | ||
| Cash receipts from return on investments | ||
| Net cash receipts from disposals of fixed assets, intangible assets and other long- term assets | 11,390,792.60 | |
| Net cash receipts from disposal of subsidiary or any other business unit | ||
| Other cash receipts relating toinvesting activities | 34,638,377.54 | 15,056,546.36 |
| Subtotal of cash inflow in investment activities | 46,029,170.14 | 15,056,546.36 |
| Cash payments to acquire or construct fixed assets, intangible assets and other long-term assets | 455,262,541.81 | 551,490,687.04 |
| Cash payments for investment | ||
| Net increase in pledged loans | ||
| Net cash payments to acquire subsidiary and other business units | ||
| Other cash payments relating to investment activities | 116,847,552.58 | 32,427,588.54 |
| Subtotal of cash outflow in investment activities | 572,110,094.39 | 583,918,275.58 |
| Net cash flow in investment activities | -526,080,924.25 | -568,861,729.22 |
| III. Cash Flows from Financing Activities: | ||
| Cash received from capital contributions | ||
| Including: Cash received from investment of minority shareholder from subsidiary | ||
| Cash receipts from borrowings | 2,468,118,080.55 | 1,857,928,465.40 |
| Other cash receipts relating to financing activities | ||
| Subtotal of cash inflow in financing activities | 2,468,118,080.55 | 1,857,928,465.40 |
| Cash repayments of borrowings | 1,825,775,003.67 | 2,143,533,066.02 |
| Cash payments for distribution of dividends, profits, or cash payments for interest expenses | 592,189,217.65 | 303,857,067.85 |
| Including: Dividends and profits paid to minority shareholders by subsidiaries | ||
| Other cash paid related to financing activities | ||
| Subtotal of cash outflow in financing activities | 2,417,964,221.32 | 2,447,390,133.87 |
| Net cash flow from financing activities | 50,153,859.23 | -589,461,668.47 |
| IV. Effect of Exchange Rate Changes on Cash and Cash Equivalents | -44,788,577.34 | 40,593,995.74 |
| V. Net Increase in Cash and Cash Equivalents | 249,100,542.55 | 622,584,935.83 |
| Add: Beginning balance of cash and cash equivalents | 1,455,356,930.03 | 1,288,636,135.42 |
| VI. Closing Balance of Cash and Cash Equivalents | 1,704,457,472.58 | 1,911,221,071.25 |
Should there be any difference in the interpretation of the contents, the Chinese version of the Third Quarter Financial Report of 2026 shall prevail.
SHANDONG WEIFANG RAINBOW CHEMICAL CO.,LTD
Board of Directors
October 28, 2026
评论 (0)